# Different Reversal Agents in Pediatric Day-case Cancer Surgery

> **NCT03996655** · PHASE4 · UNKNOWN · sponsor: **National Cancer Institute, Egypt** · enrollment: 80 (estimated)

## Conditions studied

- Post-operative Residual Curarization

## Interventions

- **DRUG:** Sugammadex Injection [Bridion]
- **DRUG:** Neostigmine

## Key facts

- **NCT ID:** NCT03996655
- **Lead sponsor:** National Cancer Institute, Egypt
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06
- **Primary completion:** 2019-09
- **Final completion:** 2019-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03996655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03996655, "Different Reversal Agents in Pediatric Day-case Cancer Surgery". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03996655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*